Want to see AGEN full AI Analyst Report?
AGEN Stock Chart & Stats
$8.36
$0.07(1.17%)
At close: 4:00 PM EDT
$8.36
$0.07(1.17%)
Day’s Range― - ―
52-Week Range$2.71 - $8.85
Previous CloseN/A
Volume97.68K
Average Volume (3M)1.36M
Market Cap
$370.97M
Enterprise Value$391.15
Total Cash (Recent Filing)$18.74M
Total Debt (Recent Filing)$40.71M
Price to Earnings (P/E)3.0
Beta1.96
Next Earnings
Nov 10, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.72
Shares Outstanding45,020,410
10 Day Avg. Volume804,676
30 Day Avg. Volume1,358,612
Financial Highlights & Ratios
PEG Ratio9.24
Price to Book (P/B)-0.34
Price to Sales (P/S)0.82
P/FCF Ratio-0.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$19.50Price Target Upside133.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.89
Revenue Forecast (FY)$136.80M
Bulls Say, Bears Say
Bulls Say
TTM Earnings TurnaroundThe latest period shows a substantial improvement in reported revenue and profitability, giving Agenus greater potential to fund development and strengthen its strategic position. If the improvement persists beyond collaboration-related timing effects, it could materially improve operating resilience over the next several quarters.
Focused Clinical StrategyAgenus is concentrating resources on a defined Phase 3 program in an earlier-stage colon cancer setting, supported by encouraging Phase 2 results cited in the financing announcement. This sharper allocation of capital can improve execution focus and create a clearer path toward a potentially meaningful oncology opportunity.
Debt ReductionThe dramatic reduction in total debt lowers absolute repayment obligations and may reduce balance-sheet pressure compared with the prior year. Although the capital structure remains constrained by negative equity, lower debt provides some improvement in financial flexibility as the company advances its clinical programs.
Bears Say
Negative Shareholder EquityPersistently negative shareholder equity indicates accumulated losses and a thin capital base, limiting Agenus’s financial flexibility. It can make future financing more consequential and increases the risk that additional capital must be raised on terms that dilute existing holders or otherwise constrain strategic choices.
Persistent Cash BurnAgenus continues to consume substantial cash despite improvement from 2025, reducing the internal funding available for research and clinical development. Ongoing negative operating and free cash flow raises the likelihood that the company will need further financing to sustain operations and reach important trial milestones.
Financing And Earnings RiskThe company’s financing structure remains costly and increasingly linked to equity issuance, which can pressure future cash resources and dilute shareholders. Combined with highly uneven historical profitability, this makes the latest earnings rebound less dependable as a durable source of funding for development.
Agenus News
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was $2.71 and its highest was $8.85 in the past 12 months.
What is Agenus’s market cap?
Agenus’s market cap is $370.97M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Nov 10, 2026 which is in 64 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Aug 06, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of $0.045 by -$0.055.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is -0.01.
How many shares outstanding does Agenus have?
Agenus has 45,020,410 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of -$0.01 in its last earnings report, missing expectations of $0.045. Following the earnings report the stock price went down -3.728%.
Which hedge fund is a major shareholder of Agenus?
Currently, no hedge funds are holding shares in AGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.50 (133.25% Upside)
$19.50 (133.25% Upside)
Blogger Sentiment
Bullish
AGEN Sentiment 67%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 18.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Agenus
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
AGEN Stock 12 Month Forecast
Average Price Target
$19.50
▲(133.25% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―
Ownership Overview
1.78% Insiders
9.33% Mutual Funds
4.57% Other Institutional Investors
75.84% Public Companies and
Individual Investors